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ABSTRACT
CDT2/L2DTL/RAMP is one of the substrate receptors of the Cullin Ring Ubiquitin
Ligase 4 that targets for ubiquitin mediated degradation a number of substrates,
such as CDT1, p21 and CHK1, involved in the regulation of cell cycle and survival.
Here we show that CDT2 depletion was alone able to induce the apoptotic death in
12/12 human cancer cell lines from different tissues, regardless of the mutation
profile and CDT2 expression level. Cell death was associated to rereplication and to
loss of CDT1 degradation. Conversely, CDT2 depletion did not affect non-transformed
human cells, such as immortalized kidney, lung and breast cell lines, and primary
cultures of endothelial cells and osteoblasts. The ectopic over-expression of an
activated oncogene, such as the mutation-activated RAS or the amplified MET in
non-transformed immortalized breast cell lines and primary human osteoblasts,
respectively, made cells transformed in vitro, tumorigenic in vivo, and susceptible to
CDT2 loss. The widespread effect of CDT2 depletion in different cancer cells suggests
that CDT2 is not in a synthetic lethal interaction to a single specific pathway. CDT2
likely is a non-oncogene to which transformed cells become addicted because of their
enhanced cellular stress, such as replicative stress and DNA damage.

INTRODUCTION

the checkpoint kinase CHK1 [13] and the TOB antiproliferative protein [14]. The CRL4CDT2 –mediated
destruction occurs mostly [2, 15] but not always [13]
through its binding to the DNA-bound fraction of the
Proliferating Cell Nuclear Antigen (PCNA). The CRL4CDT2
has also roles outside the regulation of the cell cycle. For
instance, SET8 destruction promotes also transcription
and prevents premature chromatin compaction [9,
16]. Moreover, the CRL4CDT2 targets the controller of
heterochromatin assembly Epe1 [17], the transcription
factor E2F in flies [18], the DNA polymerase η in worms
[19] and the p12 subunit of the DNA polymerase δ in
humans [20, 21], and in fission yeast the ribonucleotide
reductase inhibitor Spd1 [22].
CDT2 was first discovered for its ability to

The evolutionarily conserved Cullin Ring Ubiquitin
Ligase 4 (CRL4) E3 ligase family, together with its DDB1
adaptor, regulates a diverse set of cellular processes
including development, transcription, replication and
DNA repair [1]. Specificity is conferred by a set of more
than fifty substrate receptors, also referred to as DCAFs
(DDB1 CUL4 Associated Factors). The CRL4 bound to
the substrate receptor CDT2/L2DTL/RAMP (CRL4CDT2)
promotes the ubiquitylation of proteins in S phase and after
DNA damage [2-4]. In vertebrates, the CRL4CDT2 targets
for destruction the licensing factor CDT1 [2, 3, 5, 6], the
CDK inhibitor p21 [7, 8], the histone methyltransferase
Set8 [9-11], the histone acetyltransferases GCN5 [12],
www.impactjournals.com/oncotarget
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induce a transient increase in the proliferation rate of
human embryonal carcinoma cells [23]. In most normal
adult tissues CDT2 is barely detectable but in highly
proliferating tissues, such as testis and bone marrow [23].
CDT2 overexpression was reported in breast [24], gastric
[25] and ovarian carcinomas [26] and rhabdomyosarcomas
[27] and associated with the aggressiveness of
hepatocellular carcinomas [28]. CDT2 overexpression was
associated with the gain of 1q where the gene is located
[28] in Ewing sarcoma [29] and to the decrease of the miR30a-5p in primary colorectal carcinomas [30]. Moreover,
in diffuse large B-cell lymphoma CDT2 increase might
be due to mutation or deletion of the FBXO11 gene, that
regulates CDT2 polyubiquitylation and degradation [31,
32].
Thus, we hypothesized that CDT2 could be targeted
for cancer therapy and silenced CDT2 in human cancer
cell lines and human non-transformed cells. Here we show
that CDT2 is necessary for the survival and replication of
cancer cells, but dispensable in non-transformed cells.

CDT2 was suppressed in twelve cancer cell lines
from different human tumor tissues and shown to be
transformed and tumorigenic, and six non-transformed
human cell lines, among which four commercially
available cell lines (HK2, hTERT-HME-1, MCF 10A and
MRC-5) and two primary cultures of human cells, i.e.
Human Umbilical Vein Endothelial Cells (HUVEC) [34]
and human osteoblasts (HOB) obtained from cultures of
bone-derived cells [35]. These non-transformed cell lines
and primary cultures were selected for their expression of
CDT, that is detectable only in highly proliferating normal
cells [23]. Details of tissues of origin and mutations of
the commercially available cell lines are reported in the
Supplementary Table 1, which shows that cancer cell lines
display different mutation profiles.
CDT2 was silenced in each cell line by means of the
transient transfection of a mixture of four small interfering
RNAs, each targeting different sequence of the CDT2
mRNA. The use of this siRNA pool allows avoiding too
high concentration of each single siRNA and thus prevents
off-target effects [36]. On the contrary, pools of siRNA
targeting different mRNAs, such as those used in libraries,
results in increased off-target effects [37]. As a control,
cells were transfected with a non-targeting siRNA pool.
Supplementary Figure 1A and 3 and Figure 3 show that
these siRNAs were similarly efficient in down-modulating
CDT2 in all cell lines, including the non-transformed ones.
Depletion of CDT2 committed to death only
cancer cell lines (Figure 1A). An increased number of
active caspase-3-positive cells after CDT2 silencing was
observed in cancer cell lines, but not in non-transformed
cells (Figure 1B). These data show that CDT2 depletion
resulted in decreased viability of cancer cell lines, due

RESULTS
Loss of CDT2 affects viability of cancer cells but
not that of non-transformed cells
As we found an association between CDT2 down
modulation and the apoptotic death of ovarian cancer cells
[33], we investigated if down-modulation of CDT2 with
RNA interference was alone able to commit ovarian and
other cancer cell lines to death.

Figure 1: CDT2 suppression affects viability of cancer cells (grouped on the left), but not that of non-transformed
cells (grouped on the right). Cell lines were transfected with either the CDT2 specific (siCDT2) or a control (siCTR) small interfering
RNA pool. (A) Percentage of dead cells, measured with cytometry after cell labeling with propidium iodide: the non-transformed cell lines
and primary cell cultures (on the right) were similarly not affected by CDT2 silencing, which induced the death of all cancer cell lines (on
the left). (B) Percentage of apoptotic cells, measured with cytometry after cell labeling with an anti active caspase-3 antibody. In cancer
cell lines (SK-OV-3, HeLa and A549) the number of caspase-3 positive cells increased after CDT2 silencing that did not affect the nontransformed cell line MCF 10A. Significance was evaluated using the Student’s t-test: ** P<0.01, *P<0.05.
www.impactjournals.com/oncotarget

5993

Oncotarget

Table 1: Cell cycles of cancer and non-transformed (non tumorigenic) cell lines after CDT2 silencing. The percentage
of cells in each phase of the cell cycle is shown. Cell cycle analysis was carried out by labelling cells with propidium iodide
(PI) after 72 hour long CDT2 silencing and evaluating the PI content in each cell with cytometer.
G0/G1
S
G2/M
>G2/M
Cell line
tumorigenicity
siCTR
siCDT2 siCTR
siCDT2 siCTR
siCDT2 siCTR
siCDT2
A549
YES
63
14
22
41
13
24
2
21
DLD1
YES
47
24
19
24
26
27
8
25
EBC1
YES
45
30
34
30
16
26
5
14
HCT116
YES
39
24
31
25
24
20
6
31
HeLa
YES
40
21
21
14
25
24
14
41
HOS
YES
42
28
16
16
37
39
5
17
HS764T
YES
45
18
30
26
22
25
3
31
MG63
YES
61
30
13
9
23
43
3
18
SK-OV-3
YES
67
45
19
20
12
20
2
15
SUIT2
YES
59
23
25
39
13
28
3
10
TOV-21G
YES
50
26
22
37
26
25
2
12
U2OS
YES
43
10
20
9
33
21
4
60
HK2
NO
65
58
19
19
15
21
1
2
hTERT-HME-1 NO
72
73
15
15
11
10
2
2
HOB
NO
75
72
14
13
10
13
1
2
HUVEC
NO
63
57
14
16
20
24
3
3
MCF 10A
NO
79
78
8
9
12
12
1
1
to apoptosis activation. As shown in the Supplementary
Figure 1B, no correlation was found between cell
susceptibility to CDT2 silencing and the baseline
level of CDT2 expression. It is noteworthy that all the
cancer cell lines were susceptible to CDT2 silencing
and all the non-transformed cells showed resistance,
although in all lines a comparable protein silencing
was achieved (Supplementary Figure 1A). To further
confirm the specific effect of CDT2 silencing, both
transformed and non-transformed cells were transduced
to express shRNAs targeting a different CDT2 sequence.
Supplementary Figure 2 shows that transformed cells, but
not non-transformed cells were selectively killed by CDT2
silencing.

Ser10-phosphorylation, that is nearly absent in interphase
cells and occurs almost exclusively during mitosis [38];
histone H3 phosphorylation increases in proliferating
cells and its decrease is indicative of lack of entry into
mitosis. As shown in Supplementary Figure 2, after CDT2
silencing phospho-H3 positive cells diminished in cancer
cell lines, but not in non-transformed cell lines. These data
show that CDT2 silencing induced cell cycle blockade,
G2 arrest and rereplication in cancer cells, but not in nontransformed cells.

Loss of CDT2 causes rereplication in cancer cells,
but not in non-transformed cells

As all cancer cell lines underwent rereplication
after CDT2 depletion, we inferred that the stability of the
licencing factor CDT1 was affected. As expected, cell
treatment with the DNA damaging agent cisplatin (CDDP)
resulted in CDT1 degradation in both cancer and nontransformed cells transfected with control siRNAs (Figure
3A-B). Conversely, CDT2 silencing abrogated the CDDP
induced degradation of CDT1 in cancer cells, while it did
not affect CDT1 degradation in non-transformed cells
(Figure 3A-B). In agreement, it has been shown already
that increased level of CDT1 results in rereplication and
cell apoptotic death [39]
We assessed also the possible role of either p21 or
CHK1, that are also CRL4CDT2 substrates. As shown in
Figure 3C, p21 degradation was impaired after CDT2
depletion, but only in p53 proficient cancer cell lines (such
as TOV-21G) and not in p53 defective cancer cell lines

Loss of CDT2 affects the degradation of CDT1 in
cancer cells, but not in non-transformed cells

It has been shown [5, 7] that CDT2 depletion might
cause rereplication and G2/M arrest in cells.
We evaluated the effect of CDT2 silencing on the
cell cycle (Table 1 and Figure 2). All cancer cell lines
showed an altered cell cycle after CDT2 suppression,
while the cell cycle of non-transformed cells was not
affected (Table 1 and Figure 2). In cancer cell lines, the
number of cells in G0/G1 phase was strikingly reduced.
Moreover, accrual of cells in G2/M and increased number
of cells showing rereplication, i.e. cells showing DNA
content >G2/M (>4N), were both associated to 72 hours
long CDT2 depletion (Table 1). To better characterize the
cell cycle blockade, we examined the status of histone H3
www.impactjournals.com/oncotarget
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Figure 2: CDT2 suppression induces rereplication and cell cycle blockade in cancer cells, but not in non-transformed
cells. Analysis of the cell cycles of cancer (right panels) and non-transformed (left panels) cells after transfection with either the CDT2
specific (siCDT2) or control (siCTR) small interfering RNA pool. Only in cancer cells CDT2 silencing resulted in alterations of the cell
cycle.

Figure 3: Loss of CDT2 affects the degradation of CDT1 in cancer, but not in non-transformed cells. (A-B), Western blot
analysis of CDT1 and CDT2 proteins in cancer (A) and non-transformed (B) cell lines transfected with either CDT2 specific (siCDT2) or
control (siCTR) small interfering RNA pool and treated with 10 µM CDDP for 6 hours. (C) Western blot analysis of p21 in p53 defective
cancer cells (SK-OV-3) and in p53 proficient cancer (TOV-21G) and non-transformed (MCF 10A) cell lines, transfected as above. (D)
Cytometric analysis of cell cycles of MG63 and U2OS cancer cell lines transfected with siRNA as above for 48 hours and then incubated
in medium containing dimethylsulphoxide (DMSO) or 30nM AZD7762 CHK1 specific inhibitor for 24 hours. (E) Western blot analysis
of CDT1 in A549 cancer cells, transfected with control and CDT2 specific siRNAs as in panels A and B and treated with CDDP (10 µM),
staurosporin (1 µM), paclitaxel (10 nM) or TRAIL (100 µg/ml) for 6 hours. Significance was evaluated using the Student’s t-test: *P<0.05.
www.impactjournals.com/oncotarget
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DNA rereplication causes the death of CDT2
depleted cells

(such as SK-OV-3) and in p53 proficient non-transformed
cell lines (such as MCF-10A).
The role of CDT2 in the degradation of CHK1
in stressed cells has been already shown [13]. The
inhibition of CHK1 kinase activity in CDT2 depleted cells
resulted only in lack of G2/M arrest but did not change
rereplication (Figure 3D).
To discriminate whether CDT2 was recruited and
necessary in cancer cells because of the DNA damage
or because of the apoptotic stimulus, CDT2-depleted
cancer cells were treated with proapoptotic agents that do
not induce DNA damage such as paclitaxel, TRAIL and
staurosporin. Figure 3E shows that CDT2 depletion did
not affect CDT1 degradation that occurred in response to
the non-DNA-damaging agents.
In conclusion, these data demonstrate that CDT2 is
indispensable for CDT1 degradation in response to DNA
damage only in cancer cells.

To confirm the correlation between CDT2 depletion,
rereplication and death we used the DNA replication
inhibitor aphidicolin, which blocks cells at the G1/S
transition [40]. In cancer cell lines, cell treatment with
aphidicolin resulted in better cell survival after CDT2
silencing (Figure 4A) and blocked rereplication (Figure
4B). This shows that, after blocking the cell cycle, cancer
cells were no longer able to undergo DNA replication and
rereplication after CDT2 depletion. Reduced rereplication
resulted in increased cell survival.
Cell death follows rereplication likely because
rereplication causes DNA damage [41]. We measured
the phosphorylated γH2AX histone in CDT2 depleted
and control cells, as its phosphorylation is a reporter of
double strand breaks (DBS) in DNA [42]. As a control,
we compared cells treated with CDDP to untreated cells,

Figure 4: DNA rereplication causes the death of CDT2 depleted cells. (A) Percentage of live cells (PI neg and Annexin V
negative) after cell transfection with the CDT2 specific or control siRNAs, and after cell treatment with aphidicolin (APH, 0,25μg/ml) or
control medium with DMSO (CTR) for 48 hours. Graphs show that cell treatment with aphidicolin reduced the proapoptotic effect of CDT2
depletion. (B) Cycles of cells transfected as above and treated with aphidicolin (APH) or control medium with DMSO (CTR) as in panel
A; cell cycle analysis shows that both U-2 OS and HeLa cells were blocked at the G1 phase by the treatment with aphidicolin and did not
undergo rereplication. (C) Percentage of p-γH2AX positive cells in response to CDT2 depletion. Both cancer (U2-OS) and non-transformed
(MCF 10A) cells, transfected with control and CDT2 specific siRNAs were labeled with an antibody directed against the phosphorylated
form of γH2AX (Ser10). Labelled cells were measured using cytometry. Only in cancer cells CDT2 depletion resulted in an increase of
p-γH2AX positive cells similar to that caused in both cancer and normal cells by CDDP. In panels A and C significance was evaluated using
the Student’s t-test: ** P<0.01.
www.impactjournals.com/oncotarget
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as DNA damaging agents induce γH2AX phosphorylation.
Both cancer and non-transformed cells treated with CDDP
showed an increased phosphorylation in γH2AX (Figure
4C). Figure 4C also shows that CDT2 depletion alone
caused a similar effect in cancer cells, indicative of DNA
damage, but not in non-transformed cells.

MET oncogene (Supplementary Figure 3C); these MET
overexpressing HOB cells were previously shown to be
transformed and tumorigenic [35].
As shown also above, the non–transformed cells
were not affected by CDT2 suppression (Figure 5), while
the expression of the hyperactivated oncogenes upregulated CDT2 expression (Supplementary Figure 3) and
rendered cells susceptible to CDT2 loss (Figure 5A and
5B).
Conversely, the hTERT-HME-1 cells where the
tumor suppressor genes RB1 or PTEN were knockeddown by means of specific shRNA did not acquire a
transformed and tumorigenic phenotype [45] and were
insensitive to CDT2 loss (Figure 5B). Notably, the parental
recipient hTERT-HME-1 cells carry already a functionally
inactive TP53, because of the p.Cys176Phe mutation [45],
that is one of the most frequent TP53 mutation and has
been detected in multiple tumor types.
Altogether these data show that the acquisition of a
transformed phenotype makes cells susceptible to CDT2
loss.

The transformed phenotype makes cancer cells
addicted to CDT2
We have shown above that several cancer cell lines,
with different mutation profiles, underwent rereplication
after CDT2 suppression. We thus hypothesized that CDT2
depletion is indispensable in cancer cells because of their
basal stress phenotype associated to transformation, due
to DNA damage, DNA replication stress and mitotic stress
[43]. To understand whether the transformed phenotype
makes cancer cells “addicted” to CDT2, we converted
non-transformed cells into transformed and tumorigenic
cells and silenced CDT2. Using Lentiviral vectors,
we transduced the non-transformed, spontaneously
immortalized MCF 10A and the h-TERT immortalized
HME-1 breast epithelial cells to over-express the RAS
oncogene activated by the p-Gly13Asp mutation (referred
as KRAS G13D) (Supplementary Figure 3A and B). It was
shown previously shown that both MCF 10A and h-TERTHME-1 expressing KRAS are transformed in vitro,
i.e. able to grow in soft agar medium, and tumorigenic
in vivo, i.e. able to form tumors when xenografted in
immunocompromised mice [44, 45]. Moreover, the
primary HOBs were transduced to overexpress the

DISCUSSION
This work shows that CDT2 is indispensable for the
survival of cancer cells, but not of non-transformed cells.
Cancer cell death due to CDT2 depletion was caused by
rereplication.
CDT2 is the substrate receptor of the CRL4CDT2
ubiquitin ligase complex, which targets for destruction a
number of substrates, among which the licensing factor

Figure 5: Expression of an activated oncogene makes cells addicted to CDT2. The indicated cell populations were transfected

with either the CDT2 specific (siCDT2) or a control (siCTR) small interfering RNA pool. Percentage of dead cells, measured with cytometry
after cell labeling with propidium iodide, is shown in both panels. (A) The non-transformed MCF 10A breast cells and primary cultures
of human osteoblasts (HOBs) were transduced to express the activated KRAS oncogene (KRAS-MCF 10A) and to over-express the MET
oncogene (C42-HOB), respectively (see also Supplementary Figure 3). Both the KRAS-MCF 10A and the C42-HOB died after CDT2
silencing, while the parental cells were unaffected. (B) The non-transformed hTERT-HME-1 breast cells were transduced either to express
the activated KRAS oncogene or to express the PTEN or RB1 specific shRNA. Only the KRAS expressing hTERT-HME-1 were killed by
CDT2 silencing. Significance was evaluated using the Student’s t-test: * P<0.05.
www.impactjournals.com/oncotarget
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CDT1 [2, 3, 5, 6], the CDK inhibitor p21 [7, 8], the
checkpoint kinase CHK1 [13] and the p12 subunit of the
DNA polymerase δ [20, 21]. CDT1 is a component of the
prereplication complex that should be disassembled once
the DNA synthesis begins. The activity of CDT1 during
the cell cycle is tightly regulated by its association with
the protein geminin and by its targeting for destruction by
different ubiquitin ligase. Upon DNA damage, CDT1 is
rapidly targeted for degradation by the CRL4CDT2 complex.
This targeting safeguards genomic integrity and prevents
rereplication while DNA repair is in progress. Indeed, it
has been shown already that accumulated CDT1, because
of reduced degradation results in DNA rereplication
and cell apoptosis [39]. It has been also shown that
CDT1 destruction occurs in cells after treatment with
chemotherapeutics [46] and after UV irradiation [47,
48]. We report here that in cancer cells, but not in nontransformed cells, this mechanism was consistently
impaired by CDT2 depletion. P21 is also a substrate of
the CRL4CDT2 ubiquitin ligase. However, its involvement
in the DNA rereplication and death of the twelve cancer
cell lines studied here is unlikely as most of these lines
are p53 defective and thus generally unable to respond to
DNA damaging agents and apoptotic stimuli by increasing
p21 expression. Indeed, we found that p21 degradation
is impaired after CDT2 depletion only in p53 proficient
cancer cell lines. In case of replication stress, lack of
degradation of the checkpoint protein kinase CHK1 occurs
in CDT2 depleted cancer cells [13]. We found that CDT2
depleted cancer cells accumulated in G2/M. However,
rereplication and cell death do not depend on CHK1
reduced degradation, as cells in the presence of CHK1
inhibitor did not accumulate in G2/M but underwent
rereplication anyway. On the other side, it is not surprising
that CDT2 depleted cells arrested in G2/M showed
rereplicated DNA, because CDT1 degradation was no
longer feasible and G2/M arrest enhances rereplication
[49]. Moreover, CDT2 depleted likely accumulated the
p12 subunit of the DNA polymerase δ, that allow fork
progression after DNA damage [21].
It has been reported that the suppression of geminin,
which is the specific protein inhibitor of CDT1, induces
cell death in some, but not all, cancer cell lines, and also
in some non-transformed cells, by inducing rereplication
and activating the DNA damage checkpoint [50, 51]. We
show here that CDT2 depletion resulted effective in killing
cancer cells that are unaffected by geminin depletion [50].
One possible explanation is that CDT2 loss also results
in lack of CHK1 degradation and cell accrual in G2/M,
which as mentioned above enhances rereplication [49].
Rereplication was likely the cause of the death
of CDT2-depleted cancer cells. Cell treatment with
aphidicolin, which blocks cells at the G1/S transition [40]
blocked rereplication and improved cell viability after
CDT2 silencing. After CDT2 suppression cancer cells
underwent an apoptotic type of death, as shown by the
www.impactjournals.com/oncotarget

accumulation of active caspase-3. This is in agreement
with the finding that rereplication generates single
strand and double strand DNA breaks [52]. Indeed, we
show that rereplication was associated to the increase
of phosphorylated γH2AX histone that is the marker of
double strand breaks in DNA. These data are in agreement
with the finding of increased phosphorylation of γH2AX
histone in two cancer cell lines where components of the
CRL4CDT2 complex had been silenced [53]. It has been also
shown that CDT2 depletion causes the phosphorylation,
i.e. activation, of CHK1 [54] that follows generation of
single strand DNA. Therefore, it is likely that damageresponsive pathways sense rereplication as DNA damage
[41] and eventually trigger the apoptotic machinery if the
DNA damage repair pathways are not functioning, as in
cancer cells.
We show here that cell death, rereplication and
CDT1 accumulation after CDT2 depletion occurred
exclusively in cancer cells. This finding is important:
if DNA rereplication and cell death could be induced
selectively in cancer cells by CDT2 depletion, cancer
cells could be killed without harming normal cells.
The resistance of non-transformed cells to CDT2
depletion was unexpected, as homozygous Cdt2−/−
mouse embryos die at the two- to four-cell stage with
an abnormal nuclear morphology [55]. This implies
that in normal cells CRL4CDT2 is dispensable and one or
more alternate mechanisms of CDT1 degradation were
actively functioning while in cancer cells CRL4CDT2 is
indispensable. It is worth noting that although several
mechanisms regulate CDT1 degradation, all cancer cell
lines shown here were similarly susceptible to CDT2
loss, though they are characterized by different pattern of
mutations. This wide effect of CDT2 depletion in suggests
that CDT2 in not in a synthetic lethal relationship to
another specific gene or pathway but becomes dominant
in cancer cells.
In agreement, the addition of a hyperactivated
oncogene made transformed and tumorigenic the nontransformed cells and was alone sufficient to make
them dependent on CDT2. Thus, we propose that the
spontaneously occurring and the ectopically obtained
transformed cells are more vulnerable to the loss of CDT2,
because they are in constant need of CRL4CDT2. This
necessity might be associated to their stress phenotype,
due to DNA damage, replication stress and mitotic stress
[43]. Notably, the CRL4CDT2 complex is distinctively
recruited for CDT1 degradation after DNA damage.
The compound pattern of genetic alterations in cancer
cells leads to a constitutive level of endogenous stimuli,
which indeed results in activation of the response to DNA
damage and replication stress [56]. Although altered,
however, even cancer cells should save mechanisms that
ensure the maintenance of cell replication. This is likely
held by the same mechanisms that protect replication in
normal cells.
5998
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In line, CDT2 expression is elevated in almost all
the cancer cell lines studied here, as it is in several other
cancer cell lines and human cancer samples [24, 25, 2729]. This can be correlated to the increased proliferation
rate of cancer cells versus normal cells, as the nontransformed highly proliferating tissues such as testis and
bone marrow show an elevated level of CDT2 expression
[23]. Moreover, it has been already demonstrated that
replication stress, that could be constitutively increased
in cancer cells, determines increased expression of CDT2
in both mammalian cells [13] and fission yeast [22]. The
exquisite sensitivity of cancer cells to CDT2 loss may
explain, in part, why CDT2 overexpression is positively
selected during tumorigenesis, as it might provide cancer
cells with a selective advantage.
Interestingly, aspects of CRL4CDT2 loss are
phenocopied by cell treatment with MLN4924 [57], a
small molecule that inhibits the CRL-NEDD8-activating
enzyme (NAE), which is also effective in actively
proliferating non-transformed cells. This is expected
as conjugation of the ubiquitin-like protein NEDD8 is
required to activate all the CRL ligases. Thus, inhibiting
the NAE by MLN4924 prevents destruction of numerous
substrates of the CRLs, involved in cell proliferation and
cancer pathways, such as not only CDT1 and p21, but also
cyclins and checkpoint kinases [26, 39, 57, 58]. Therefore,
treatment of cancer cells with MLN4924 triggers
rereplication, DNA damage, G2 arrest, and apoptosis.
MLN4924 is currently in clinical trials as an anticancer
agent [59].
Altogether, data shown here suggest that cancer
cells share some properties that make them “addicted”
to CDT2. The term “oncogene addiction” [60] has
been invented to pinpoint the dependence of cancer
cells on a mutated cancer gene for tumor initiation and
maintenance. One facet of oncogene addiction is synthetic
lethality, as cancer cells might become addicted to a given
oncogene when they lose a redundant gene or pathway
that is in synthetic lethal interaction with the oncogenic
pathway [61, 62]. Moreover, activation of an oncogene
or loss of a tumor suppressor gene might install a flood
of genetic, transcriptional and metabolic alterations
[63-66] that make the cancer gene the only “dam to the
flood” of pro-apoptotic signals [67]. Therefore, despite
the focus on causative oncogenes as targets of cancer
therapeutics, there is solid experimental evidence for nononcogenes that are rate-limiting to their pathways and
represent potential drug targets. This phenomenon has
been termed “non-oncogene addiction” in reference to
the increased dependence of cancer cells on the normal
cellular functions of certain genes, which themselves are
not classical oncogenes [43]. Here we show that several
cancer cell lines, which derive from diverse tissues and
show different genetic alterations, all require CDT2 for
proliferation and survival and are thus addicted to this
non-oncogene. We can infer that CDT2 is in synthetic
www.impactjournals.com/oncotarget

lethal interaction with different oncogenic pathway, the
most likely Achille’s heel being the stress phenotype of
cancer cells, due to the DNA damage represented by the
widespread genetic aberration and the replication and
mitotic stress caused by uncontrolled proliferation.

METHODS
Cell lines, chemicals and antibodies.
Twelve cancer cell lines (Table S1) from different
human tumors and the non-transformed human cell
lines HK2, hTERT-HME1, MCF 10A and MRC-5 cell
lines were purchased from the American Type Culture
Collection (Manassas, VA) and grown as suggested by
the provider. Primary cultures of human cells HUVEC
and osteoblasts (HOB) were obtained as previously
described [34, 35]. MCF 10A and hTERT-HME-1 cells
were engineered to overexpress the KRAS G13D cDNA
by infection with a Lentiviral vector harboring the mutated
KRAS allele downstream a constitutive promoter as
previously reported [45]. C42 MET over-expressing HOB
clone were obtained as previously reported [35]. Details of
other reagents are described in Supplementary Materials
and Methods.

RNA Interference
RNAi experiments were performed using ONTARGET plus SMART pool, a mixture of four siRNAs
targeting one gene (Dharmacon, Lafayette,CO). In each
experiment ON-TARGET plus Non-Targeting Pool
(Dharmacon, Lafayette, CO) was used as negative control.
The sequences of the oligonucleotides are reported in
Supplementary Materials and Methods. Cell lines were
plated at 30-40% confluence and transfected with the
indicated siRNA pools (200nM) using Oligofectamine
(Invitrogen, Eugene, OR) according to the manufacturer’s
instructions. The mRNA downmodulation of target genes
was assayed with quantitative RT-PCR and with Western
Blot analysis 48h and 72h after transfection, respectively.
Experiments were performed 72 hours after transfection,
if not otherwise indicated.

RNA extraction and Quantitative Reverse
Transcription-PCR
RNA extraction and qPCR was carried out as
described previously [33]. Details are reported in
Supplementary Materials and Methods.
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Protein extraction and Western Blot analysis

control replication licensing. Genes Dev 2008; 22, 25072519.

Total protein extraction was performed by directly
incubating cells in SDS containing lysis buffer at 95°C
for 5 minutes. Proteins were separated by PAGE and
transferred to nitrocellulose sheets. Equal amounts of
proteins (100 µg) were loaded in each lane. Blots were
probed and when necessary re-probed with the different
antibodies as indicated in the Result section. Bound
antibodies were detected using the appropriate peroxidaseconjugated secondary antibody and revealed by Enhanced
Chemiluminescence (Amersham, United Kingdom).
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